Logo

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Share this

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Shots:

  • The P-III study involves assessing JZP-258 vs PBO in 201 patients with narcolepsy + cataplexy prior treated with Xyrem- naive to Xyrem- or with/without anti-cataplectic treatments
  • The P-III study results: met its 1EPs & 2EPs; reduction in no. of cataplexy attacks in a week and Epworth Sleepiness Scale score
  • JZP-258 is an oxybate therapy targeting GABAB receptor with a unique composition of cations resulting in 92% less sodium than Xyrem (sodium oxybate) and is evaluated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy & idiopathic hypersomnia. Jazz also plans to file NDA for JZP-258 based on above results

  Ref: Jazz Pharmaceuticals | Image: Studios Architecture

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions